MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$2,939K
Free Cash flow
-$651K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Accrued expenses and other curre...
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Accounts receivable, net
    • Prepaid expenses and other curre...
    • Net loss
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-330
-581
-819
-534
Depreciation
32
33
34
36
Stock-based compensation
58
135
24
39
Deferred tax asset
-
-
-
-141
Deferred income tax expense
0
431
-107
-
Operating lease right-of-use asset
-40
-38
161
-56
Accounts receivable, net
650
168
-340
78
Inventories, net
81
-19
40
-208
Prepaid expenses and other current assets
364
86
392
15
Deferred consideration, net of discount
24
61
62
59
Accounts payable
216
282
229
-666
Accrued expenses and other current liabilities
391
148
78
158
Withholding tax payable
63
99
109
110
Operating lease liabilities
-40
-39
162
-56
Deferred revenue
-8
-29
-449
0
Net cash used in operating activities
-649
-519
-764
-635
Purchases of property and equipment
2
29
47
10
Net cash used in investing activities
-2
-29
-47
-10
Proceeds from issuance of common stock, net of offering expenses
3,536
161
266
0
Proceeds from exercise of employee stock options
0
0
0
21
Payments for fractional shares related to reverse-split
-
0
0
0
Principal payments on short-term debt
82
51
56
83
Insurance premiums financed
-
277
-
-
Net cash provided by (used in) financing activities
3,454
387
210
-62
Effect of exchange rate on cash and cash equivalents
136
-1
127
137
Net increase (decrease) in cash and cash equivalents
2,939
-162
-474
-570
Cash and cash equivalents, beginning of period
2,399
3,035
3,035
5,374
Cash and cash equivalents, end of period
5,338
2,399
2,561
3,035
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock, net of...$3,536K Net cash provided by(used in) financing...$3,454K (6055.17%↑ Y/Y)Effect of exchange rateon cash and cash...$136K (-66.83%↓ Y/Y)Canceled cashflow$82K Net increase(decrease) in cash and cash...$2,939K (266.14%↑ Y/Y)Canceled cashflow$651K Principal payments onshort-term debt$82K (1.23%↑ Y/Y)Accrued expenses andother current...$391K (180.79%↑ Y/Y)Accounts payable$216K (-78.95%↓ Y/Y)Withholding tax payable$63K (-39.42%↓ Y/Y)Stock-based compensation$58K (1.75%↑ Y/Y)Operating leaseright-of-use asset-$40K (-108.93%↓ Y/Y)Depreciation$32K (-11.11%↓ Y/Y)Deferred consideration,net of discount$24K (-56.36%↓ Y/Y)Net cash used inoperating activities-$649K (67.79%↑ Y/Y)Net cash used ininvesting activities-$2K (98.11%↑ Y/Y)Canceled cashflow$824K Accounts receivable, net$650K (200.93%↑ Y/Y)Purchases of property andequipment$2K (-98.11%↓ Y/Y)Prepaid expenses andother current assets$364K (-55.56%↓ Y/Y)Net loss-$330K (73.41%↑ Y/Y)Inventories, net$81K (-87.58%↓ Y/Y)Operating leaseliabilities-$40K (-108.93%↓ Y/Y)Deferred revenue-$8K (-130.77%↓ Y/Y)

Sonoma Pharmaceuticals, Inc. (SNOA)

Sonoma Pharmaceuticals, Inc. (SNOA)